2024-10-19 08:54:00
The president of Sanofi France confirmed on Saturday that the operation is close to closing with the American CD&R fund, despite the relaunch of the PAI fund.
Sanofi is concluding negotiations with the American fund CD&R for the sale of its Doliprane manufacturing subsidiary despite the improved offer proposed by a French competitor, the president of Sanofi France confirmed in an interview published Saturday in the Courrier Picard. «After a traditional process, a partner was identified ten days ago. We are finalizing negotiations with him. It is a growth project», declared Audrey Duval, when asked about the improved offer announced on Thursday by the French fund PAI for the takeover of its subsidiary Opella.
On Thursday evening the French pharmaceutical giant had already said”surprised» of this offer excluded “deadlines», remembering his choice from the previous week. Sanofi announced on October 11 that it was in talks with the American investment fund CD&R to potentially sell it 50% of Opella, its subsidiary which is home to a hundred brands of over-the-counter products around the world, including Doliprane.
This strategic project, a new example of “Big Pharma” refocusing on innovation, quickly took a political turn given the popularity of the drug used to relieve pain and fever in French society.
#Sanofi #finalizing #sale #American #fund #CDR